Monopar Therapeutics Inc (MNPR) - Total Assets
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) holds total assets worth $137.98 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore MNPR cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Monopar Therapeutics Inc - Total Assets Trend (2015–2025)
This chart illustrates how Monopar Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Monopar Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
Monopar Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Monopar Therapeutics Inc's total assets of $137.98 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Monopar Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MNPR company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Monopar Therapeutics Inc's current assets represent 99.8% of total assets in 2025, an increase from 71.7% in 2015.
- Cash Position: Cash and equivalents constituted 43.9% of total assets in 2025, down from 70.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Monopar Therapeutics Inc Competitors by Total Assets
Key competitors of Monopar Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Monopar Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 56.04 | 36.92 | 22.10 |
| Quick Ratio | 56.04 | 36.92 | 22.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $135.29 Million | $53.58 Million | $23.28 Million |
Monopar Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Monopar Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 2.81 |
| Asset Growth Rate (YoY) | 133.4% |
| Total Assets | $140.72 Million |
| Market Capitalization | $395.88 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Monopar Therapeutics Inc's assets at a significant premium (2.81x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Monopar Therapeutics Inc's assets grew by 133.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Monopar Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $140.72 Million | +133.40% |
| 2024-12-31 | $60.29 Million | +720.83% |
| 2023-12-31 | $7.35 Million | -44.47% |
| 2022-12-31 | $13.23 Million | -35.55% |
| 2021-12-31 | $20.52 Million | +21.66% |
| 2020-12-31 | $16.87 Million | +26.34% |
| 2019-12-31 | $13.35 Million | +82.46% |
| 2018-12-31 | $7.32 Million | -26.31% |
| 2017-12-31 | $9.93 Million | +242.98% |
| 2016-12-31 | $2.90 Million | +2.39% |
| 2015-12-31 | $2.83 Million | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more